Skip to main content
SAM CHUN DANG PHARM CO. LTD logo

SAM CHUN DANG PHARM CO. LTD — Investor Relations & Filings

Ticker · 000250 ISIN · KR7000250001 KO Manufacturing
Open in API
Filings indexed 224 across all filing types
Latest filing 2021-03-18 Report Publication Anno…
Country KR South Korea
Listing KO 000250

About SAM CHUN DANG PHARM CO. LTD

http://www.scd.co.kr/english/scd/index.…

SAM CHUN DANG PHARM CO. LTD. is a pharmaceutical company focused on the development, manufacturing, and sale of medications. The company specializes in ophthalmic products, establishing itself as a significant player in the generic eye care market. Its portfolio also extends to other therapeutic areas, including antibiotics and medications for the circulatory system. The company produces a range of ethical (prescription) and over-the-counter (OTC) drugs in both sterile and non-sterile forms. Manufacturing operations adhere to international quality standards, holding both US and EU Good Manufacturing Practice (GMP) certifications.

Recent filings

Filing Released Lang Actions
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is an official announcement regarding an upcoming Investor Relations (IR) event (기업설명회). It provides details such as the date, time, location, purpose, and registration method for the meeting. Since this is an announcement of an event rather than the presentation slides themselves, and it serves as a regulatory notification of corporate activity, it fits the definition of a Regulatory Filing (RNS) or a general announcement of corporate events.
2021-03-18 Korean
사업보고서 (2020.12)
Audit Report / Information Classification · 98% confidence The document is a 'Consolidated Audit Report' (연결감사보고서) for Samchundang Pharm Co., Ltd. It includes the independent auditor's report, consolidated financial statements (balance sheet, income statement, statement of changes in equity, cash flow statement), and notes to the financial statements for the fiscal years 2019 and 2020. This is a formal audit document, not an annual report (10-K) which would include management discussion and analysis (MDA) and other business disclosures, nor is it an earnings release. It fits the definition of an Audit Report (AR). FY 2020
2021-03-15 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of Annual General Meeting' (주주총회소집공고) for Samchundang Pharm Co., Ltd. It contains the meeting agenda, details on voting procedures (including electronic voting), and financial statements (balance sheet, income statement, etc.) for the 77th fiscal year. In the context of Korean regulatory filings (DART), this document is classified as a Proxy Solicitation & Information Statement (PSI) because it provides shareholders with the necessary information to vote on agenda items, including director appointments and financial approvals, prior to the meeting.
2021-03-05 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea (often filed under the Financial Supervisory Service's DART system) used to solicit shareholder votes for an upcoming Annual General Meeting (AGM). It contains information about the meeting date, agenda items (such as approval of financial statements, director appointments, etc.), and instructions for electronic voting. This falls under the 'Proxy Solicitation & Information Statement' category.
2021-03-02 Korean
증권발행결과(자율공시)
Capital/Financing Update Classification · 100% confidence The document is a formal announcement regarding the 'Results of Securities Issuance' (증권 발행결과) for a private placement of convertible bonds (전환사채). It details the issuance amount, payment date, and conversion terms. This falls under the category of capital structure changes and financing activities, specifically matching the 'Capital/Financing Update' (CAP) category.
2021-02-26 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a formal regulatory filing titled '감사보고서 제출' (Submission of Audit Report) submitted by Samchundang Pharm. It contains key financial data, audit opinions, and financial statements for the fiscal year. While it provides financial highlights, it is a standard regulatory disclosure of the audit report submission rather than the full 10-K annual report document itself. Therefore, it is classified as an Audit Report / Information document. FY 2020
2021-02-26 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.